Péptidos

A synthetic peptide for use as a blocking control in assays to test for specificity of ACAT2 antibody, catalog no. 70R-1083

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCD4 antibody, catalog no. 70R-1784

A synthetic peptide for use as a blocking control in assays to test for specificity of SPTAN1 antibody, catalog no. 70R-2207

A synthetic peptide for use as a blocking control in assays to test for specificity of DYDC1 antibody, catalog no. 70R-4150

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM120C antibody, catalog no. 70R-10170

A synthetic peptide for use as a blocking control in assays to test for specificity of ALDH3A1 antibody, catalog no. 70R-9874

A synthetic peptide for use as a blocking control in assays to test for specificity of PUS1 antibody, catalog no. 70R-10363

A synthetic peptide for use as a blocking control in assays to test for specificity of RPAIN antibody, catalog no. 70R-8518

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of Gcom1 antibody, catalog no. 70R-3275

A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp275 antibody, catalog no. 70R-8773

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPE1 antibody, catalog no. 70R-4219

A synthetic peptide for use as a blocking control in assays to test for specificity of DUS1L antibody, catalog no. 70R-4013

A synthetic peptide for use as a blocking control in assays to test for specificity of CHCHD3 antibody, catalog no. 70R-4356

A synthetic peptide for use as a blocking control in assays to test for specificity of NRP1 antibody, catalog no. 70R-9671

CD2, human, recombinant is a research peptide that is commonly used in scientific studies. It is a protein that is produced using Escherichia Coli bacteria. CD2 plays an important role in immune responses and cell signaling. This recombinant form of CD2 allows researchers to study its function and interactions with other molecules in a controlled laboratory setting. It can be used in various experiments and assays to investigate the mechanisms of immune system regulation and develop potential therapeutic interventions. With its high purity and quality, CD2, human, recombinant is a valuable tool for researchers in the field of immunology and molecular biology.

A synthetic peptide for use as a blocking control in assays to test for specificity of NSMCE1 antibody, catalog no. 70R-2769

A synthetic peptide for use as a blocking control in assays to test for specificity of AKR1C1 antibody, catalog no. 70R-10003

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF286 antibody, catalog no. 70R-8091

A synthetic peptide for use as a blocking control in assays to test for specificity of UBE2L3 antibody, catalog no. 70R-3085

A synthetic peptide for use as a blocking control in assays to test for specificity of ZDHHC21 antibody, catalog no. 70R-4550

A synthetic peptide for use as a blocking control in assays to test for specificity of FCRL1 antibody, catalog no. 70R-1853

HG1 toxin is a peptide that is found in the venom of the scorpion Heterometrus fulvipes. It is a member of the short-chain scorpion toxins, which are composed of a single chain of amino acids. This protein has been shown to bind to potassium channels and inhibit their function, leading to paralysis of the prey's nervous system. HG1 toxin has been shown to be able to activate or inhibit ion channels and other receptors. It can also bind to ligands such as peptides or antibodies and affect cellular activity. HG1 toxin is produced by recombinant DNA technology and purified by HPLC for use in biochemical research and pharmacological studies.

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of FOXN4 antibody, catalog no. 70R-8770

A synthetic peptide for use as a blocking control in assays to test for specificity of ASL antibody, catalog no. 70R-1176

A synthetic peptide for use as a blocking control in assays to test for specificity of RNF121 antibody, catalog no. 70R-6550

A synthetic peptide for use as a blocking control in assays to test for specificity of GJA8 antibody, catalog no. 70R-6106

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP2R1 antibody, catalog no. 70R-8833

A synthetic peptide for use as a blocking control in assays to test for specificity of C20orf18 antibody, catalog no. 70R-1161

A synthetic peptide for use as a blocking control in assays to test for specificity of LANCL2 antibody, catalog no. 70R-2713

A synthetic peptide for use as a blocking control in assays to test for specificity of ANKRD39 antibody, catalog no. 70R-9456

A synthetic peptide for use as a blocking control in assays to test for specificity of AIFM3 antibody, catalog no. 70R-2470

A synthetic peptide for use as a blocking control in assays to test for specificity of SH3RF1 antibody, catalog no. 70R-2622

MOG(35-55) human corresponds to amino acids 35 to 55 of the human myelin oligodendrocyte glycoprotein (MOG). It can be used in multiple sclerosis research to induce experimental autoimmune encephalomyelitis (EAE) in mouse and rat models.

Bovine Serum Albumin (BSA) is a protein that is used in the pharmaceutical industry as a research tool and an immunological reagent. BSA can be used to bind, stabilize, and prevent denaturation of other proteins in the laboratory. It has been shown to inhibit ion channels and ligand-gated ion channels, which are important for membrane potentials. BSA is also an activator of receptor tyrosine kinases, which are involved in cell signaling pathways.

A synthetic peptide for use as a blocking control in assays to test for specificity of DDX19A antibody, catalog no. 70R-1339

A synthetic peptide for use as a blocking control in assays to test for specificity of ASXL2 antibody, catalog no. 70R-3526

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC14A1 antibody, catalog no. 70R-7059

Anti IL-1alpha (Rat) Serum is a serum that provides an inhibitor for IL-1alpha. The serum is used in the study of peptides and cell biology. This serum is made from high purity, life science grade material and has been shown to be effective in inhibiting the activation of ion channels.

A synthetic peptide for use as a blocking control in assays to test for specificity of POGZ antibody, catalog no. 20R-1216

1-Deoxyfructosyl-Val-His (1DFVH) is a research tool that belongs to the group of activators. It has been shown to activate receptors and ion channels, as well as inhibit antibody production. 1DFVH also has an effect on cell biology, which may be due to its ability to interact with proteins in a variety of ways. 1DFVH binds to the receptor by competitive inhibition and activates the receptor by mimicking the natural ligand. This compound has been shown to activate ion channels in cells through the opening of potassium channels, leading to depolarization and increased calcium influx into cells.

A synthetic peptide for use as a blocking control in assays to test for specificity of C21orf13 antibody, catalog no. 70R-1973

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNJ9 antibody, catalog no. 70R-5156

Cysteine peptide (Ac RFAAKAA COOH) is used in combination with Lysinepeptide (Ac RFAACAA COOH) in the Direct Peptide Reactivity Assay (DPRA) test.
Direct Peptide Reactivity Assay is used in cosmetic applications for the characterization of the skin sensitizing potential of a substance, framed by OECD Guideline no 442.
The molecular initiating event (MIE) in skin sensitization is a binding between epidermal proteins and the sensitizing chemical substance. MIE is part of the adverse outcome pathway (AOP) of skin sensitization.
It is thanks to the properties of Lysine peptide and Cysteine peptide that the chemical binding will be able to take place, so these synthetic heptapeptides will mimic the reaction of a skin exposed to a substance.
Binding between nucleophilic proteins and electrophile substance will be measured by High Performance Liquid Chromatography (HPLC). Therefore, the decrease in Lysine peptide and Cysteine peptide levels will be a sign of sensitizing event. Depending on the rate of depletion, the sensitizing character of a molecule will be determined (see table at the bottom of the page).
In chemico DPRA test also has wider applications such as hazard classification in cosmetics, but also for pharmaceuticals and biocides. It is a good alternative to animal experimentation.

A synthetic peptide for use as a blocking control in assays to test for specificity of C1orf122 antibody, catalog no. 70R-4043

A synthetic peptide for use as a blocking control in assays to test for specificity of EDIL3 antibody, catalog no. 70R-9143

AMC is a peptide that acts as an activator of the nicotinic acetylcholine receptor. AMC is a high-purity, ion channel ligand with a CAS No. 26093-31-2. It is used in life science research to study cell biology and pharmacology. AMC has been shown to be an inhibitor of the enzyme acetylcholinesterase (AChE) in rat brain slices and it has been reported that it can inhibit the proliferation of human leukemia cells.END>

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity